日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

RNase1-driven ALK-activation is an oncogenic driver and therapeutic target in non-small cell lung cancer

RNase1驱动的ALK激活是非小细胞肺癌的致癌驱动因素和治疗靶点。

期刊:Signal Transduction and Targeted Therapy
影响因子:40.8
doi:10.1038/s41392-025-02206-x
Zhengyu Zha # ，Chunxiao Liu # ，Meisi Yan # ，Cong Chen # ，Cheng Yu ，Yaohui Chen ，Chenhao Zhou ，Lu Li ，Yi-Chuan Li ，Hiro Yamaguchi ，Leiguang Ye ，Tong Liu ，Ying-Nai Wang ，Heng-Huan Lee ，Wen-Hao Yang ，Li-Chuan Chan ，Baozhen Ke ，Jennifer L Hsu ，Lieming Ding ，Dong Ji ，Peng Pan ，Yiran Meng ，Yue Pu ，Lunxu Liu ，Mien-Chie Hung
肺癌
细胞生物学
肿瘤
ALK
肿瘤免疫
发表日期：2025
文献求助 收藏

Tibremciclib or Placebo Plus Fulvestrant in Hormone Receptor-Positive and ERBB2-Negative Advanced Breast Cancer After Endocrine Therapy: A Randomized Clinical Trial

替布西尼或安慰剂联合氟维司群治疗内分泌治疗后激素受体阳性、ERBB2阴性晚期乳腺癌：一项随机临床试验

期刊:Jama Oncology
影响因子:20.1
doi:10.1001/jamaoncol.2025.2092
Tao, Zhonghua; Zhang, Jian; Zheng, Qiufan; Wang, Yongsheng; Cai, Li; Xu, Hongyan; Xu, Xinhua; Kong, Xiangshun; Ding, Sijuan; Hao, Chunfang; Wang, Hao; Zong, Hong; Jin, Xin; Wang, Xinshuai; Li, Yang; Yang, Xiuli; Li, Weijie; Du, Xiaoya; Chen, Hui; Wu, Pengxiang; Li, Peiqi; Mao, Li; Ding, Lieming; Hu, Xichun; Wang, Shusen
肿瘤
肿瘤免疫
ERBB2
信号转导
乳腺癌
免疫/内分泌
发表日期：2025
文献求助 收藏

Positional variability of a small intestinal stromal tumor: a case report

小肠间质瘤位置变异性：病例报告

期刊:Journal of Surgical Case Reports
影响因子:0.5
doi:10.1093/jscr/rjaf874
Luo, Song; Xv, Lieming; Huang, Chuanli
发表日期：2025
文献求助 收藏

Updated overall survival and circulating tumor DNA analysis of ensartinib for crizotinib-refractory ALK-positive NSCLC from a phase II study

来自一项 II 期研究的恩沙替尼治疗克唑替尼耐药的 ALK 阳性非小细胞肺癌的最新总生存期和循环肿瘤 DNA 分析

期刊:Cancer Communications
影响因子:24.9
doi:10.1002/cac2.12524
Zheng, Jing; Wang, Tao; Yang, Yunpeng; Huang, Jie; Feng, Jifeng; Zhuang, Wu; Chen, Jianhua; Zhao, Jun; Zhong, Wei; Zhao, Yanqiu; Zhang, Yiping; Song, Yong; Hu, Yi; Yu, Zhuang; Gong, Youling; Chen, Yuan; Ye, Feng; Zhang, Shucai; Cao, Lejie; Fan, Yun; Wu, Gang; Guo, Yubiao; Zhou, Chengzhi; Ma, Kewei; Fang, Jian; Feng, Weineng; Liu, Yunpeng; Zheng, Zhendong; Li, Gaofeng; Wang, Huijie; Cang, Shundong; Wu, Ning; Song, Wei; Liu, Xiaoqing; Zhao, Shijun; Ding, Lieming; Selvaggi, Giovanni; Wang, Yang; Xiao, Shanshan; Wang, Qian; Shen, Zhilin; Zhou, Jianya; Zhou, Jianying; Zhang, Li
肺癌
肿瘤
肿瘤免疫
ALK
细胞生物学
发表日期：2024
文献求助 收藏

Discovery and preclinical evaluation of BPB-101: a novel triple functional bispecific antibody targeting GARP-TGF-β complex/SLC, free TGF-β and PD-L1

BPB-101 的发现和临床前评估：一种新型三功能双特异性抗体，靶向 GARP-TGF-β 复合物/SLC、游离 TGF-β 和 PD-L1

期刊:Frontiers in Immunology
影响因子:5.9
doi:10.3389/fimmu.2024.1479399
Xu, Wenxin; Xu, Jieying; Li, Pingcui; Xu, Deyu; Cheng, Hongjie; Zheng, Huan; Zhang, Li; Liu, Mengmeng; Ye, Siyuan; Jiang, Mengshi; Yu, Wenqi; Wang, Jiabing; Ding, Lieming
PD-L1
TGF-β
发表日期：2024
文献求助 收藏

Application of the ESMO Magnitude of Clinical Benefit Scale to assess the clinical benefit of antibody drug conjugates in solid cancer: a systematic descriptive analysis of phase III and pivotal phase II trials

应用ESMO临床获益程度量表评估抗体药物偶联物在实体瘤治疗中的临床获益：一项对III期和关键性II期试验的系统性描述性分析

期刊:BMJ Open
影响因子:2.3
doi:10.1136/bmjopen-2023-077108
Ding, Lieming; Yuan, Xiaobin; Wang, Yang; Shen, Zhilin; Wu, Pengxiang
SMO
发表日期：2024
文献求助 收藏

Safety, efficacy and pharmacokinetics of BPI-9016M in c-MET overexpression or MET exon 14 skipping mutation patients with locally advanced or metastatic non-small-cell lung cancer: a phase Ib study

BPI-9016M 在 c-MET 过表达或 MET 14 号外显子跳跃突变的局部晚期或转移性非小细胞肺癌患者中的安全性、有效性和药代动力学：一项 Ib 期研究

期刊:BMC Cancer
影响因子:3.4
doi:10.1186/s12885-022-10500-y
Hu, Xingsheng; Cui, Xinge; Wang, Ziping; Liu, Yunpeng; Luo, Ying; Zhong, Wei; Zhao, Hui; Yao, Mengxing; Jiang, Da; Wang, Mingxia; Chen, Minjiang; Zheng, Xin; Ding, Lieming; Wang, Yang; Yuan, Xiaobin; Wu, Pengxiang; Hu, Bei; Han, Xiaohong; Shi, Yuankai
肺癌
肿瘤
肿瘤免疫
细胞生物学
MET
发表日期：2023
文献求助 收藏

Comparison of the diagnostic efficiency between the O-RADS US risk stratification system and doctors' subjective judgment

O-RADS美国风险分层系统与医生主观判断的诊断效能比较

期刊:BMC Medical Imaging
影响因子:3.2
doi:10.1186/s12880-023-01153-9
Zhou, Shan; Guo, Yuyang; Wen, Lieming; Liu, Jieyu; Fu, Yaqian; Xu, Fang; Liu, Minghui; Zhao, Baihua
发表日期：2023
文献求助 收藏

A retrospective study of ensartinib-treated ALK-positive locally advanced or metastatic NSCLC patients in China

中国接受恩沙替尼治疗的ALK阳性局部晚期或转移性非小细胞肺癌患者的回顾性研究

期刊:Lung Cancer Management
影响因子:0.7
doi:10.2217/lmt-2023-0005
Yuan, Xiaobin; Wang, Yang; Yang, Min; Wu, Pengxiang; Chen, Hui; Yun, Yu; Shen, Zhilin; Ji, Dong; Ma, Yongbin; Ding, Lieming
肺癌
肿瘤
肿瘤免疫
ALK
细胞生物学
发表日期：2023
文献求助 收藏

Vorolanib, a novel tyrosine receptor kinase receptor inhibitor with potent preclinical anti-angiogenic and anti-tumor activity

沃罗拉尼是一种新型酪氨酸受体激酶受体抑制剂，具有强效的临床前抗血管生成和抗肿瘤活性

期刊:Molecular Therapy-Oncolytics
影响因子:5.3
doi:10.1016/j.omto.2022.01.001
Chris Liang, Xiaobin Yuan, Zhilin Shen, Yang Wang, Lieming Ding
肿瘤
发表日期：2022
文献求助 收藏